Navigation Links
Omixon Founder, Attila Berces Returns as CEO, Aims to Roll-Out New Products

Global molecular diagnostics company Omixon, headquartered in Budapest with US offices in Cambridge, MA, announced today that Omixon’s founder and chairman Dr. Attila Berces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialisation of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017.

In concert between the incoming and outgoing CEOs, as well as Omixon’s Board of Directors, the company has restructured its executive team with Gregory Werner as VP Commercial Operations, Elmar Schilling as CTO, and Judit Kósa as CFO. Gregory Werner joined Omixon from Thermo Fisher where he was responsible for the entire One Lambda portfolio (Transplant Diagnostics) in Europe. Prior to the acquisition by One Lambda, Greg built the European operations for Linkage Biosciences, successfully introducing LinkSeq™ and dominating the market. Elmar Schilling has joined Omixon from Eurofins Genomics, where he led the NGS Manual Innovation Facility at its DNA Campus near Munich. Judit Kósa, joins Omixon after more than a decade in the pharmaceutical industry including Teva Pharmaceuticals and AMRI and more than a decade in CFO roles. "Together with Zoltán Simon (COO), who has been with the company for over 10 years, Omixon's executive team is ready to take Omixon to a new level," says Dr. Berces.

Omixon came to the market with the first HLA genotyping test using Next Generation Sequencing (NGS) in 2014 and has grown revenues at a compounded annual rate of 100% for four consecutive years. “During the fast pace of market expansion we had failed to listen to some customer requirements. We are now addressing this and will provide laboratories with an improved customer experience. We recently released a software update that solved a serious software performance issue. We are committed to continue with our outstanding customer support. We have an ambitious vision to expand our product portfolio by developing new products in-house, as well as by licensing and acquiring new innovative technologies,” says Dr. Berces.

Omixon’s R&D lab continues to operate during the current lock-down. It is an excellent time to gather customer input, improve existing products and develop new ones. The Early Access Program of the 11-locus multiplex Omnitype product is already underway with feedback from 8 labs and while partly interrupted by COVID19, the product versions tested in the second phase of the EAP will incorporate the feedback from those first 8 labs with minimal impact to EAP. We aim to fulfil laboratory expectations and we strive to bring at least one new product on the market every year.

Despite the general economic uncertainty of COVID19, Omixon’s profitability and excellent relationship with its long-term investors allows the company capitalize on growth opportunities with new products in 2020.

Contacts at Omixon
Gregory Werner
VP Commercial Operations

Nora Nagy, MBA
Market Development Manager

About Omixon
Omixon is a global molecular diagnostics company, headquartered in Budapest, Hungary, with US offices in Cambridge, MA that commercializes disruptive technologies for clinical and research laboratories. Omixon’s flagship product, Holotype HLA, is the world’s leading NGS-based HLA genotyping product that delivers the most accurate high-resolution HLA genotyping available, and is used in more than 50 hospitals worldwide. Omixon’s research software, HLA Explore analyzes data from any sequencing technology and determines HLA genotypes from Whole Exome/Genome Sequencing experiments. Omixon maintains an active grant-funded research program with a product pipeline focused on pre- and post-transplantation, and HLA genotyping applications beyond transplantation. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. Omixon’s OmniType is Now Available Under Early Access
2. Omixon and TBG form Partnership for Asia Pacific
3. Omixon Announce CE Mark for Holotype HLA
4. Omixon Announces Dimitri Monos as Chair of its Scientific Advisory Board
5. Omixon Announce Major Tender Victory in France
6. Omixon Holotype HLA validation Alpha Study featured at ASHI Annual Meeting 2014
7. Omixon Collaborates with G3 and Genomics England to Validate HLA Genotyping from WGS Data
8. Omixon Launches Holotype HLA for NGS-based HLA Genotyping
9. VetStem Biopharma CEO and Founder, Dr. Bob Harman, Interviewed in New Book "Stem Cell Therapy: A Rising Tide"
10. Animated Dynamics, Inc. Co-Founder, Dr. David Nolte, Receives Award From Purdue University For Commercial Patent
11. Ernst & Young announces Proove Biosciences CEO and Founder, Brian Meshkinas an EY Entrepreneur Of The Year™ 2015 Award Semifinalist in Orange County
Post Your Comments:
(Date:6/28/2020)... ... June 26, 2020 , ... ... solutions providers, today announced its strong opposition to the recently introduced bicameral ... a blanket ban on most federal use of nearly all biometric and related ...
(Date:6/23/2020)... , ... June 22, 2020 , ... ... glutamine antagonist, DRP-104, will be presented June 22-24 during the American Association for ... DRP-104; and, the other profiles the potent, consistent single agent activity in KEAP1 ...
(Date:6/11/2020)... ... June 09, 2020 , ... PathSensors ... a Small Business Innovation Research (SBIR) program funded by the National Institute of ... Detection in the Field”. The project’s goal was to engineer and develop a ...
(Date:6/2/2020)... (PRWEB) , ... June 01, 2020 , ... ... hand to companies and encourage positive change in the world, enterprise security solutions ... pandemic. , With more people working from home during self-quarantines and shelter-in-place orders, ...
Breaking Biology Technology:
(Date:5/28/2020)... , ... May 27, 2020 , ... CrucialTrak, a global ... with New Jersey-based Critical Environments Group (CEG) to market and sell its complete line ... data center and IT environment infrastructure optimization solutions . , Brett Mason, ...
(Date:5/26/2020)... FRANCISCO (PRWEB) , ... May ... ... provider of enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone ... of T-cell receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has ...
(Date:5/21/2020)... ... May 20, 2020 , ... Catalent, ... drugs, biologics, cell and gene therapies, and consumer health products, today announced that ... be presenting at the ISCT 2020 Paris Virtual conference, which takes place on ...
Breaking Biology News(10 mins):